- Report
- October 2024
- 190 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Drug Pipelines
- July 2024
- 100 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- October 2024
- 185 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 372 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- November 2024
- 171 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2025
- 250 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 185 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- June 2024
- 145 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Clinical Trials
- April 2024
- 230 Pages
Global
From €2852EUR$3,000USD£2,396GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- May 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- July 2024
- 200 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- May 2024
- 140 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- August 2024
- 240 Pages
Europe
From €2177EUR$2,290USD£1,829GBP
- Report
- January 2024
- 69 Pages
Europe
From €2524EUR$2,655USD£2,120GBP
€2804EUR$2,950USD£2,356GBP
- Report
- February 2024
- 82 Pages
Asia Pacific
From €2524EUR$2,655USD£2,120GBP
€2804EUR$2,950USD£2,356GBP
- Report
- May 2023
- 166 Pages
Global
From €2377EUR$2,500USD£1,997GBP

The Breast Cancer Diagnostics market is a subset of the larger Diagnostics industry. It is focused on the development and commercialization of products and services that aid in the early detection and diagnosis of breast cancer. These products and services include imaging technologies such as mammography, ultrasound, and MRI, as well as biopsy and other tissue sampling techniques. Additionally, the market includes a range of molecular diagnostics, such as gene expression profiling and circulating tumor DNA tests.
The Breast Cancer Diagnostics market is driven by the increasing prevalence of breast cancer, as well as the need for early detection and diagnosis. Additionally, technological advancements in imaging and molecular diagnostics have enabled the development of more accurate and cost-effective tests.
Notable companies in the Breast Cancer Diagnostics market include Hologic, GE Healthcare, Siemens Healthineers, Philips, and Roche Diagnostics. Show Less Read more